繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
Processa Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Processa Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Processa Pharmaceuticals | 10-Q:2024財年三季報
牛牛AI助理已提取核心訊息
Processa Pharmaceuticals, Inc. (Processa), a clinical-stage biopharmaceutical company, reported its financial performance for the quarter ended September 30, 2024. The company's financials showed a net loss of $3.4 million for the quarter, compared to a net loss of $2.1 million for the same period in 2023. Research and development expenses increased to $2.3 million, up from $1.2 million in the previous year, primarily due to the ongoing Phase 1B trial and initiation of the Phase 2 trial for NGC-Cap, a next-generation chemotherapy drug. General and administrative expenses also rose to $1.1 million from $1.0 million year-on-year. The company's cash and cash equivalents stood at $2.9 million as of September 30, 2024. Processa has been financing its operations through public equity issuances, including a recent offering that raised...Show More
Processa Pharmaceuticals, Inc. (Processa), a clinical-stage biopharmaceutical company, reported its financial performance for the quarter ended September 30, 2024. The company's financials showed a net loss of $3.4 million for the quarter, compared to a net loss of $2.1 million for the same period in 2023. Research and development expenses increased to $2.3 million, up from $1.2 million in the previous year, primarily due to the ongoing Phase 1B trial and initiation of the Phase 2 trial for NGC-Cap, a next-generation chemotherapy drug. General and administrative expenses also rose to $1.1 million from $1.0 million year-on-year. The company's cash and cash equivalents stood at $2.9 million as of September 30, 2024. Processa has been financing its operations through public equity issuances, including a recent offering that raised net proceeds of $6.3 million. The company also received $931,000 from an 'at the market offering' under a sales agreement. Processa is currently conducting a Phase 2 trial for NGC-Cap in breast cancer patients and is in discussions to extend deadlines for other drug development milestones with its licensors. The company's future plans include continuing the Phase 2 trial for NGC-Cap and evaluating other next-generation chemotherapy drugs in its portfolio. Processa's ability to continue operations is dependent on obtaining additional funding, and there is substantial doubt about its ability to continue as a going concern without such funding.
Processa Pharmaceuticals, Inc.(Processa)是一家臨床階段生物製藥公司,報告了截至2024年9月30日的季度財務表現。公司的財務數據顯示,該季度淨損失爲340萬美元,相比2023年同期的210萬美元淨損失有所增加。研發費用增加至230萬美元,較去年的120萬美元有所增長,主要是由於正在進行的第10億階段試驗以及新一代化療藥物NGC-Cap的第2期試驗的啓動。一般和管理費用也從去年的100萬美元上升至110萬美元。截至2024年9月30日,公司的現金及現金等價物爲290萬美元。Processa一直通過公開發行股份等方式籌集資金,包括最近一次募集淨收益630萬美...展開全部
Processa Pharmaceuticals, Inc.(Processa)是一家臨床階段生物製藥公司,報告了截至2024年9月30日的季度財務表現。公司的財務數據顯示,該季度淨損失爲340萬美元,相比2023年同期的210萬美元淨損失有所增加。研發費用增加至230萬美元,較去年的120萬美元有所增長,主要是由於正在進行的第10億階段試驗以及新一代化療藥物NGC-Cap的第2期試驗的啓動。一般和管理費用也從去年的100萬美元上升至110萬美元。截至2024年9月30日,公司的現金及現金等價物爲290萬美元。Processa一直通過公開發行股份等方式籌集資金,包括最近一次募集淨收益630萬美元的發行。公司還根據一項銷售協議從「市場發行」中獲得了93.1萬美元。Processa目前正在對NGC-Cap在乳腺癌患者中進行第2期試驗,並正在與許可方商討延長其他藥物開發里程碑的截止日期。公司的未來計劃包括繼續進行NGC-Cap的第2期試驗,並評估其投資組合中其他新一代化療藥物。Processa繼續運營的能力取決於獲得額外資金,且在缺乏此類資金的情況下,公司能否繼續作爲一個持續經營的實體存在仍存疑。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間